New data from Allergan Aesthetics shows GLP-1 weight-loss treatments are driving increased demand for aesthetic procedures, with facial volume loss emerging as a key concern among patients.
Written By: Karthik Teja, PharmD
Reviewed By: Dr. Swati-Deore-Pawar, BAMS,
ACCR, PGDCC,
Aesthetic Cosmetologist
Allergan Aesthetics, part of AbbVie, has released new data showing how the rapid uptake of medical weight-loss treatments is reshaping patient behaviour and treatment demand in aesthetic medicine. The company reports that patients using GLP-1–based weight-loss therapies are increasingly seeking aesthetic procedures to address facial volume loss and other visible changes associated with rapid weight reduction.
Medical Weight Loss Driving New Aesthetic Concerns
According to Allergan Aesthetics’ consumer and physician research, patients undergoing medical weight loss (MWL) frequently experience noticeable facial changes, particularly loss of midface volume, skin laxity, and deeper facial lines. These concerns are prompting many patients, including first-time aesthetic consumers, to seek professional treatments aimed at restoring facial balance and skin structure.
The data indicates that facial volume loss is the most common aesthetic concern, affecting 61% of patients using GLP-1 therapies. Other reported issues include skin laxity in 50% of patients and facial wrinkles or folds in 35%. Rapid weight loss is believed to accelerate these changes, creating demand for proactive consultation and personalized treatment plans.
Growing Demand for Aesthetic Procedures
Allergan’s analysis also highlights a sharp rise in interest in physician-administered aesthetic treatments among patients undergoing medical weight loss. Approximately 40% of MWL patients are considering aesthetic procedures performed in physician offices or medical spas, signaling a growing intersection between obesity medicine and aesthetic dermatology.
At the same time, aesthetic clinics are increasingly becoming entry points for weight-loss care. Around 60% of consumers using GLP-1 medications now receive them from healthcare providers who also offer aesthetic treatments, up from roughly half just one year earlier.
This shift suggests a more integrated care model in which weight management and aesthetic medicine are delivered within the same clinical setting.
Dermal Fillers Emerging as Key Treatment Option
Physicians responding to Allergan’s surveys reported a clear increase in demand for treatments that address facial volume loss after significant weight reduction. Hyaluronic acid dermal fillers have emerged as one of the most frequently used nonsurgical interventions.
About 81% of healthcare providers identified hyaluronic acid fillers as a primary treatment option for patients experiencing facial changes following GLP-1–related weight loss. Additionally, one-third of physicians (33%) reported that GLP-1 therapy has increased the overall number of dermal filler injections performed in their practices.
Clinical Insights and Physician Perspectives
Allergan Aesthetics has been studying the intersection of medical weight loss and aesthetic medicine since early 2022. The company recently presented related findings at the American Society for Dermatologic Surgery Annual Meeting in 2025.
Further insights were published in January 2026 in the Aesthetic Surgery Journal Open Forum in an article titled “Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations.”
Commenting on the findings, dermatologist Joely Kaufman said the data reflects what many physicians are already seeing in clinical practice.
“Medical weight loss can significantly change facial appearance,” Kaufman explained. “Patients who are excited about their weight-loss success often seek personalized and medically appropriate solutions that help restore facial balance and confidence.”
Preparing Providers for a Changing Patient Population
Allergan Aesthetics said the growing popularity of GLP-1 therapies is introducing a new category of patients to aesthetic medicine. These individuals often arrive with different priorities, focusing on restoring facial harmony and maintaining natural-looking results as their body transformation progresses.
Glen Curran, Senior Vice President at Allergan Aesthetics, said the company is working to equip healthcare providers with education, consultation tools, and data-driven insights to support this evolving patient population.
As the use of GLP-1–based weight-loss medications continue to expand globally, the company believes aesthetic medicine will increasingly play a role in helping patients manage the visible effects of rapid weight loss and maintain overall facial balance.
References
Allergan Aesthetics Highlights Medical Weight Loss (MWL) Data and the Changing Profile of Patients, 04 March 2026, ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS – Mar 4, 2026
Moradi A et al, Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations. Aesthet Surg J Open Forum. 2026 Jan 21; PMID: 41768029; PMCID: PMC12937588. https://doi.org/10.1093/asjof/ojag011
Expert Opinion
Dr. Swati Pawar-Deore, leading cosmetologist and owner of an aesthetic clinic, noted that the growing use of GLP-1–based weight-loss medicines is increasingly being reflected in aesthetic practice. “GLP-1 therapies help regulate appetite and metabolic health and are now widely used for medical weight management, which has led to more patients visiting aesthetic clinics after rapid weight loss,” she said. According to Dr. Pawar-Deore, one emerging concern is the so-called “Ozempic face,” where significant and rapid fat loss leads to facial volume depletion, skin laxity, and hollow cheeks that can create a prematurely aged appearance. “In such cases, patients often seek corrective aesthetic treatments such as dermal fillers, collagen stimulators, or skin-tightening procedures to restore facial volume and improve skin firmness,” she explained.
About Writer
Karthik Teja, Pharm.D.
He is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.